🧬 Terry Lo - Vizgen - Part 2 | Terry’s Move from Big Pharma to Diagnostics | Introduction to Spatial Biology | Navigating Regulatory & Reimbursement Challenges in Diagnostics | Balancing Multiple Roles in M&A Negotiations

episode

The Biotech Startups Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-21-2026 7AM EDT 4 min · 21 Sep 2026 · NPR News Now

#573 - Becoming Conductors 1h 20m · 21 Sep 2026 · The Basement Yard

Google fined €403m by Irish data watchdog 3 min · 21 Sep 2026 · Today with David McCullagh

Reaction to Patrick Clancy on 60 Minutes 7 min · 21 Sep 2026 · Today with David McCullagh

What Career Should You Choose in the AI Age? 32 min · 21 Sep 2026 · Merryn Talks Money

NPR News: 09-21-2026 6AM EDT 5 min · 21 Sep 2026 · NPR News Now

Report any issue

Source

Recorded10 Apr 2024

Publisherfeeds.fame.so ↗

Handlerec:3386598

Show notes

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in